Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of idelalisib in patient with chronic lymphocytic leukemia or lymphoma relapsing after allogeneic hematopoietic cell transplantation

Next Previous
X
Search
Trial Profile

Safety and efficacy of idelalisib in patient with chronic lymphocytic leukemia or lymphoma relapsing after allogeneic hematopoietic cell transplantation

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 22 Dec 2017 As of June 22, 2017, a total of 28 patients had been registered according to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 22 Dec 2017 New trial record
    • 12 Dec 2017 Results (n=24) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top